Zim Laboratories
BSE: ZIMLAB · Pharmaceuticals
Snapshot
Unlock Zim Laboratories's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zim Laboratories is a research-driven pharmaceutical company specialising in the development and manufacture of oral solid dosage forms. The company provides both pre-formulation intermediates and finished formulations for pharmaceutical and nutraceutical segments.
Business Model
The company generates revenue by leveraging its in-house R&D capabilities to offer non-infringing drug delivery solutions and generic products. It operates as a manufacturer and supplier with international quality certifications including EU-GMP and WHO-GMP.
Growth Outlook
Growth is driven by the company's focus on proprietary process technologies and the expansion of its generic product portfolio. Continued investment in R&D aims to support the development of specialised drug delivery solutions for global markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent international quality standards, and any failure to maintain certifications like EU-GMP could disrupt export operations.
- Pricing Pressure. The generic pharmaceutical sector faces intense price competition, which may impact profit margins on finished formulations.
- R&D Execution. Success depends on the ability to develop non-infringing drug delivery solutions that remain competitive and legally viable in global markets.
- Foreign Exchange Volatility. As an exporter of pharmaceutical products, the company is exposed to fluctuations in currency exchange rates affecting international revenue.
Start your research today
Unlock AI insights, financials, peers and live data on Zim Laboratories and 5,000+ companies — free.
Key Metrics
REVENUE
₹374 Cr
TTM · consolidated
NET PROFIT
₹6 Cr
TTM · consolidated
EPS
₹1.19
TTM · consolidated
RETURN ON EQUITY
2.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.8%
TTM · consolidated
P/E
103.3x
Q4 FY26 · consolidated
EV/EBITDA
10.5x
Q4 FY26 · consolidated
EBITDA MARGIN
11.1%
TTM · consolidated
NET PROFIT MARGIN
3.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Zim LaboratoriesZIMLAB | ₹672 Cr | 153.00 | 19.69 | 7.6% | 9.9% | 1.3% | 5.7% | +66.4% |
Amanta HealthcarAMANTA | ₹719 Cr | 44.50 | 13.94 | — | 21.5% | 6.7% | 9.9% | — |
Influx Health.INFLUX | ₹701 Cr | — | — | — | 20.0% | — | — | +77.5% |
Shree Ganesh Remedies LimitedSGRL | ₹696 Cr | 39.23 | 18.75 | — | 34.8% | 11.9% | 15.9% | -7.6% |
Bafna Pharmaceuticals LimitedBAFNAPH | ₹689 Cr | 88.48 | 40.61 | -3.1% | 12.5% | 8.6% | 10.3% | +180.3% |
Kilitch Drugs (India) LimitedKILITCH | ₹601 Cr | 13.70 | 14.07 | 14.0% | 20.2% | 12.1% | 15.6% | -49.4% |
As of Q1 FY27
Financials
Zim Laboratories
BSE: ZIMLAB · Pharmaceuticals
Snapshot
Unlock Zim Laboratories's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zim Laboratories is a research-driven pharmaceutical company specialising in the development and manufacture of oral solid dosage forms. The company provides both pre-formulation intermediates and finished formulations for pharmaceutical and nutraceutical segments.
Business Model
The company generates revenue by leveraging its in-house R&D capabilities to offer non-infringing drug delivery solutions and generic products. It operates as a manufacturer and supplier with international quality certifications including EU-GMP and WHO-GMP.
Growth Outlook
Growth is driven by the company's focus on proprietary process technologies and the expansion of its generic product portfolio. Continued investment in R&D aims to support the development of specialised drug delivery solutions for global markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent international quality standards, and any failure to maintain certifications like EU-GMP could disrupt export operations.
- Pricing Pressure. The generic pharmaceutical sector faces intense price competition, which may impact profit margins on finished formulations.
- R&D Execution. Success depends on the ability to develop non-infringing drug delivery solutions that remain competitive and legally viable in global markets.
- Foreign Exchange Volatility. As an exporter of pharmaceutical products, the company is exposed to fluctuations in currency exchange rates affecting international revenue.
Start your research today
Unlock AI insights, financials, peers and live data on Zim Laboratories and 5,000+ companies — free.
Key Metrics
REVENUE
₹374 Cr
TTM · consolidated
NET PROFIT
₹6 Cr
TTM · consolidated
EPS
₹1.19
TTM · consolidated
RETURN ON EQUITY
2.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.8%
TTM · consolidated
P/E
103.3x
Q4 FY26 · consolidated
EV/EBITDA
10.5x
Q4 FY26 · consolidated
EBITDA MARGIN
11.1%
TTM · consolidated
NET PROFIT MARGIN
3.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27